Amiodarone Drug Interactions in Heart Failure – Key Points
Amiodarone Drug Interactions in Heart Failure – Key Points
1️⃣ Negative Chronotropes & Conduction-Slowing Agents
Drugs involved:
• β-blockers
• Digoxin
• Verapamil / Diltiazem (non-DHP CCBs)
• Ivabradine
• Clonidine
2️⃣ Other Antiarrhythmics & QT-Prolonging Agents
Risk of combination:
• QTc prolongation
• Torsade de pointes (TdP)
• Proarrhythmia (especially IV amiodarone)
Clinical guidance:
• Avoid combining with other QT-prolonging drugs unless absolutely necessary
• Reserve dual therapy for life-threatening ventricular arrhythmias
• Monitor QTc closely
3️⃣ Diuretics & Electrolyte-Disturbing Therapies
Electrolyte abnormalities that increase risk:
• Hypokalemia
• Hypomagnesemia
• Hypocalcemia
Common contributing therapies:
• Loop and thiazide diuretics
• Laxatives
• Systemic corticosteroids
• IV amphotericin B
• Severe or prolonged diarrhea
Clinical principle:
• Correct electrolytes before and during amiodarone therapy
• Monitor K⁺ and Mg²⁺ regularly
4️⃣ Anticoagulation Interaction
Warfarin interaction:
• Amiodarone increases INR
Clinical action:
• Frequent INR monitoring after initiation
• Warfarin dose reduction often required
5️⃣ Device Therapy (ICD / Pacemaker Context)
• May alter pacing thresholds
• May alter defibrillation thresholds
Recommendation:
• Reassess device parameters after starting amiodarone
Summary Teaching Pearl
In heart failure patients, amiodarone interactions primarily involve:
• Bradycardia & conduction delay
• QT prolongation & TdP risk
• Electrolyte-mediated proarrhythmia
• Warfarin potentiation
• Device threshold changes
Medscape Reference
Last updated: February 2026
